title: Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine.
abstract: Transitional cell carcinoma (TCC) is the most common bladder tumor. Urine cytology can identify most high-grade tumors but sensitivity is lower if one includes lesions of all grades. Microsatellite marker alterations have been found in many tumor types including bladder cancer and have been used to detect cancer cells in body fluids including urine. The aim of our study is to further evaluate feasibility and sensitivity of microsatellite analysis to detect bladder cancer cells in urine. We studied 55 individuals: 21 with symptoms suggestive of bladder cancer, 23 patients with previous history of TCC and 11 healthy subjects. Genomic DNA was extracted from blood lymphocytes, urine sediment, bladder washings and tumor or normal bladder mucosa. Twenty highly informative microsatellite markers were analyzed for loss of heterozigosity (LOH) and microsatellite instability (MIN) by polymerase chain reaction. Microsatellite analysis of urine identified 33 of 34 (97%) patients with either primary or tumor recurrence, whereas urine cytology identified 27 of 34 (79%) patients (p = 0.0001). Detection of microsatellite abnormalities improved the sensitivity of detecting low-grade and/or stage bladder tumor: from 75-95% for grades G1-G2 and from 75-100% for pTis-pTa tumors. Bladder washings from 25 patients were also analyzed, and in all cases results were identical to those obtained from voided urine. None of the 16 patients without evidence of TCC showed LOH and/or MIN in urine samples or bladder washings. Interestingly, in a patient with persistent bladder mucosa abnormalities, microsatellite alterations were demonstrated 8 months before the histopathologic diagnosis of tumor recurrence. These results further indicate that microsatellite marker analysis is more sensitive than conventional urine cytology in detecting bladder cancer cells in urine and represents a potential clinical tool for monitoring patients with low-grade/stage TCC.
authors.affiliation: Unità Patologia Molecolare e Terapia Genica, IRCCS H. Casa Sollievo Sofferenza, Opera Padre Pio da Pietrelcina, San Giovanni Rotondo, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Seripa
authors.forename: P
authors.initials: P
authors.lastname: Parrella
authors.forename: M
authors.initials: M
authors.lastname: Gallucci
authors.forename: C
authors.initials: C
authors.lastname: Gravina
authors.forename: S
authors.initials: S
authors.lastname: Papa
authors.forename: P
authors.initials: P
authors.lastname: Fortunato
authors.forename: A
authors.initials: A
authors.lastname: Alcini
authors.forename: G
authors.initials: G
authors.lastname: Flammia
authors.forename: M
authors.initials: M
authors.lastname: Lazzari
authors.forename: V M
authors.initials: VM
authors.lastname: Fazio
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis* / Q000235:genetics / Q000652:urine*; D005260:Female; D006801:Humans; D019656:Loss of Heterozygosity; D008297:Male; D018895:Microsatellite Repeats / Q000235:genetics*; D008875:Middle Aged; D016622:Silver Staining; D019680:Trinucleotide Repeat Expansion; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000652:urine*